Result for
Tag: vaccines
April 27, 2021
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021
The Advisory Committee on Immunization Practices (ACIP) reaffirmed its interim recommendation for use of the Johnson & Johnson vaccine in all persons aged ≥18 years on April 23, 2021 and recommended including a warning that rare clotting events may occur in female vaccine recipients aged 18-49 years. The updated recommendations follow the recommended pause by…
April 22, 2021
Preliminary Findings of MRNA Covid-19 Vaccine Safety in Pregnant Persons
Among women in the V-safe pregnancy registry who reported completing pregnancy after receiving COVID-19 mRNA vaccines (Pfizer-BioNTech or Moderna) from December to February 201 (n=827), adverse pregnancy and neonatal outcomes occurred in similar proportions as previously studies of pregnant women conducted before the COVID-19 pandemic. 14% resulted in pregnancy loss, 86% resulted in live birth…
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
The SARS-CoV-2 single-dose adenovirus vector vaccine Ad26.COV2.S (Johnson & Johnson) protected against moderate to severe-critical COVID-19 ≥14 days after administration with 66.9% efficacy (95% CI: 59-73.4%) in a randomized, double-blind placebo-controlled phase 3 trial. 116 cases occurred among those receiving the vaccine (n=19,691) vs 348 cases in the placebo group (n=19,691). Efficacy ≥28 days after…
Effectiveness of the BNT162b2 Vaccine in Preventing COVID-19 in the Working Age Population – First Results from a Cohort Study in Southern Sweden
[Pre-print, not peer-reviewed] The Pfizer-BioNTech vaccine was 86% effective in preventing infection >7 days after the second dose in a cohort study (n=806,000) in Sweden from December 2020 to February 2021. Effectiveness was only 42% >14 days after a single dose. The vaccinated population largely consisted of healthcare workers. SARS-CoV-2 incidence among unvaccinated individuals with…
April 20, 2021
Safety and Immunogenicity of SARS-CoV-2 Recombinant Protein Vaccine Formulations in Healthy Adults: Interim Results of a Randomised, Placebo-Controlled, Phase 1–2, Dose-Ranging Study
The SARS-CoV-2 recombinant protein vaccine candidate CoV2 preS dTM (Sanofi Pasteur) was safe and immunogenic in a randomized Phase I/II trial (n=439) but elicited lower immune responses than anticipated. Both a one and two dose regimen were tested but a single vaccine dose did not generate neutralizing antibody titers above placebo levels in any group….
Identification of Natural SARS-CoV-2 Infection in Seroprevalence Studies among Vaccinated Populations
[Pre-print, not peer-reviewed] Anti-nucleocapsid protein (N) antibodies were found to be an accurate method for differentiating between antibodies produced by natural infection and antibodies produced in response to vaccination, according to a study of healthcare workers (n=82). Participants were tested for anti-spike (S) IgG antibodies and anti-N IgG at two time points. No participants were…
April 15, 2021
Neutralizing Activity of Sputnik V Vaccine Sera against SARS-CoV-2 Variants
[Pre-print, not peer-reviewed] Neutralizing antibody activity induced by SARS-CoV-2 adenovirus vector vaccine Sputnik V had geometric mean titers (GMT) that were reduced by 6.8-fold against a pseudovirus bearing B.1.351 spike protein mutations when compared to the prototypic D614G strain. GMT reduction was reduced by 2.8-fold against the pseudovirus with the E484K mutation alone. Among the…
INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T Cell Activity Against Global SARS-CoV-2 Variants
[Pre-print, not peer-reviewed] Neutralizing antibody activity induced by the SARS-CoV-2 vaccine candidate INO-4800 (Inovia Pharmaceuticals), a DNA-based vaccine, was reduced against variants of concern B.1.1.7 and B.1.351 compared to the wild-type strain by 2.1 and 6.9-fold, respectively. In contrast, neutralizing activity was maintained against the P.1 variant, which harbors the same E484K mutation as B.1.351…
April 7, 2021
Efficient Maternofetal Transplacental Transfer of Anti- SARS-CoV-2 Spike Antibodies after Antenatal SARS-CoV-2 BNT162b2 MRNA Vaccination
In a study of women who received the Pfizer (SARS-CoV-2 BNT162b2) vaccine, all 20 women and infants had detectable anti S- and anti-RBD-specific IgG. Anti-S and anti-RBD-specific IgG antibody levels in maternal sera were positively correlated to their respective concentrations in cord blood (correlation rho= 0.72; P<0.001 and correlation rho= 0.72; P <0.001, respectively) suggesting…
Unraveling Attributes of COVID-19 Vaccine Hesitancy in the U.S. A Large Nationwide Study
[Pre-print, not peer-reviewed] A study conducted in December 2020-January 2021, among 34,470 US users of a COVID-19-focused smartphone-based app found that 83% of respondents were accepting of the vaccine. Among users who expressed vaccine hesitancy, the majority were undecided about accepting vaccination. Vaccine hesitancy was significantly higher among females, younger people, minority and low-income communities,…
Previous page Next page